Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $4.62, a high estimate of $8.00, ...

Drug development is a very challenging and often arduous process with many associated ... Finally, please provide an overview of using MPS to enhance preclinical safety and toxicity testing.

According to a report by Mordor Intelligence, the clinical diagnostics market has a size of $88.79 billion as of 2025.

Over the years, there has been an increasing demand for an effective and cost-efficient drug discovery process. The study of ...

We recently published a list of the 12 Best Diagnostics Stocks to Invest In Right Now. In this article, we are going to take ...

Q4 2024 Earnings Call Transcript March 24, 2025 Operator: Hello, and welcome to the Moleculin Biotech Fourth Quarter and Full ...

ORIC-944, a PRC2 inhibitor with best-in-class properties, restores luminal features and restricts adaptation in prostate cancer models, conferring synergy with AR pathway inhibitors ORIC-944 is a ...

Q4 2024 Earnings Call Transcript March 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...

Net research and development expenses for the device division increased in 2024 to CAD175,000 from CAD44,000 in 2023, a 400% increase. The increase is attributed to development of a new software ...

VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative ...